According to Dr Fotin-Mleczek, the technology has been previously tested in a rabies vaccine.
She said: “The work is currently in its first phase of research, on healthy people, on whom we test the safety of our vaccine and try to figure out what does is needed to obtain an adequate immune response.
“Ongoing research has shown that a very low dose, even one microgram, is enough to cause a human antibody level that gives us protection.
“This level of antibodies is set by the World Health Organization (WHO).
“We get here a very clear, legible, unambiguous answer whether the technology is able to provide immune protection or not.”